Soleno Therapeutics Statistics
Share Statistics
Soleno Therapeutics has 50.39M
shares outstanding. The number of shares has increased by 25.94%
in one year.
| Shares Outstanding | 50.39M |
| Shares Change (YoY) | 25.94% |
| Shares Change (QoQ) | 6.35% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 174 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 4.16M, so 8.26% of the outstanding
shares have been sold short.
| Short Interest | 4.16M |
| Short % of Shares Out | 8.26% |
| Short % of Float | 9.51% |
| Short Ratio (days to cover) | 4.38 |
Valuation Ratios
The PE ratio is -10.27 and the forward
PE ratio is 7444.
Soleno Therapeutics's PEG ratio is
-0.12.
| PE Ratio | -10.27 |
| Forward PE | 7444 |
| PS Ratio | 0 |
| Forward PS | 3.2 |
| PB Ratio | 7.37 |
| P/FCF Ratio | -26.05 |
| PEG Ratio | -0.12 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Soleno Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.68,
with a Debt / Equity ratio of 0.22.
| Current Ratio | 15.68 |
| Quick Ratio | 15.68 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | -0.3 |
| Debt / FCF | -0.76 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,529,130.43 |
| Employee Count | 115 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 62.53% in the
last 52 weeks. The beta is -2.67, so Soleno Therapeutics's
price volatility has been lower than the market average.
| Beta | -2.67 |
| 52-Week Price Change | 62.53% |
| 50-Day Moving Average | 63.89 |
| 200-Day Moving Average | 53.27 |
| Relative Strength Index (RSI) | 55.44 |
| Average Volume (20 Days) | 1,315,725 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -184.43M |
| Net Income | -175.85M |
| EBITDA | -173.63M |
| EBIT | -175.62M |
| Earnings Per Share (EPS) | -4.38 |
Full Income StatementBalance Sheet
The company has 87.93M in cash and 52.83M in
debt, giving a net cash position of 35.1M.
| Cash & Cash Equivalents | 87.93M |
| Total Debt | 52.83M |
| Net Cash | 35.1M |
| Retained Earnings | -452.26M |
| Total Assets | 330.97M |
| Working Capital | 275.14M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -69.1M
and capital expenditures -218K, giving a free cash flow of -69.31M.
| Operating Cash Flow | -69.1M |
| Capital Expenditures | -218K |
| Free Cash Flow | -69.31M |
| FCF Per Share | -1.73 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
